Sage Therapeutics Inc. (NASDAQ:SAGE) – Leerink Swann issued their FY2020 earnings per share estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Thursday. Leerink Swann analyst P. Matteis forecasts that the brokerage will post earnings of $2.21 per share for the year. Leerink Swann currently has a “Outperform” rating and a $68.00 target price on the stock.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.10) by $0.05.

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus began coverage on shares of Sage Therapeutics in a research report on Monday. They issued a “buy” rating and a $90.00 target price on the stock. BMO Capital Markets reissued a “buy” rating and issued a $57.00 price target on shares of Sage Therapeutics in a report on Friday, August 12th. Zacks Investment Research raised shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Cowen and Company reissued a “buy” rating on shares of Sage Therapeutics in a report on Thursday, November 3rd. Finally, Canaccord Genuity set a $110.00 price target on shares of Sage Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $69.54.

Shares of Sage Therapeutics (NASDAQ:SAGE) opened at 51.60 on Monday. The company has a 50 day moving average of $44.18 and a 200-day moving average of $38.51. The firm’s market cap is $1.92 billion. Sage Therapeutics has a 12-month low of $26.28 and a 12-month high of $62.64.

In related news, CFO Kimi Iguchi sold 2,500 shares of Sage Therapeutics stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $40.93, for a total transaction of $102,325.00. Following the completion of the transaction, the chief financial officer now directly owns 81,239 shares of the company’s stock, valued at approximately $3,325,112.27. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of SAGE. Bank of New York Mellon Corp boosted its position in shares of Sage Therapeutics by 13.0% in the second quarter. Bank of New York Mellon Corp now owns 104,010 shares of the biopharmaceutical company’s stock worth $3,134,000 after buying an additional 11,978 shares during the period. Alps Advisors Inc. boosted its position in shares of Sage Therapeutics by 25.1% in the second quarter. Alps Advisors Inc. now owns 45,044 shares of the biopharmaceutical company’s stock worth $1,357,000 after buying an additional 9,036 shares during the period. Candriam Luxembourg S.C.A. boosted its position in shares of Sage Therapeutics by 7.2% in the second quarter. Candriam Luxembourg S.C.A. now owns 74,000 shares of the biopharmaceutical company’s stock worth $2,230,000 after buying an additional 5,000 shares during the period. RS Investment Management Co. LLC boosted its position in shares of Sage Therapeutics by 1.8% in the second quarter. RS Investment Management Co. LLC now owns 586,826 shares of the biopharmaceutical company’s stock worth $17,681,000 after buying an additional 10,435 shares during the period. Finally, Eagle Asset Management Inc. boosted its position in shares of Sage Therapeutics by 3.2% in the second quarter. Eagle Asset Management Inc. now owns 873,924 shares of the biopharmaceutical company’s stock worth $26,331,000 after buying an additional 27,319 shares during the period. 85.82% of the stock is owned by institutional investors.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.